

## Table of Contents

	<b>Description</b>	<b>Page No.</b>
	List of Tables	v
	List of Figures	vii
	List of Abbreviations and symbols	xii
	Preface	xiii
<b>1</b>	<b>Introduction</b>	<b>1</b>
<b>2</b>	<b>Literature Review</b>	
	2.1 Ovarian Cancer	6
	2.2 Nanocarriers in drug delivery	7
	2.3 Nanocarriers in anticancer therapy	8
	2.4 Lipid based drug delivery systems	9
	2.5 Nanostructured Lipid Carriers (NLCs)	10
	2.5.1 Type of NLCs:	11
	2.6 Polymeric Nanoparticles:	12
	2.7 Excipients profile	
	2.7.1 Poly (lactic co glycolic) acid (PLGA):	13
	2.7.2 Poloxamer 188:	14
	2.7.3 Capmul MCM (Glyceryl Caprylate/Caprate):	16
	2.7.4 Vitamin E TPGS (D- $\alpha$ - tocopherol polyethylene glycol 1000 Succinate)	16
	2.7.5 Tristearin:	17
	2.8 Drugs profile	
	2.8.1 Paclitaxel (PTX):	18
	2.8.2 Genistein:	21
	2.9 Design of Experiment (DoE) in Drug Delivery:	24
<b>3</b>	<b>Research envisage &amp; Plan of Work</b>	
	3.1 Aim	26
	3.2 Objectives	26

3.3 Rationale of the study	26
3.4 Plan of Work	27
<b>4 Materials &amp; Methods</b>	
4.1 Material and equipments	
4.1.1 Materials used	30
4.1.2 Equipments used	31
4.1.3 Software's used	32
4.2 Preformulation Studies	
4.2.1 HPLC analytical & bioanalytical method development	32
4.2.2 Synergism analysis of ratiometric drug combination	33
4.3 Formulation development of Nanostructured Lipid Carriers	
4.3.1 Method of preparation	33
4.3.2 Optimization of process and product Parameters for Blank NLCs	34
4.3.3 Screening of Factors by Placket Burman Design	35
4.3.4 Optimization by Box Behnken methodology	35
4.4 Formulation development of polymeric nanoparticles	
4.4.1 Method of preparation	36
4.4.2 Optimization of blank nanoparticles by Box Behnken methodology (BBD)	36
4.5 Characterization studies	
4.5.1 Drug Excipient compatibility studies	
Fourier Transformed Infrared studies (FTIR)	37
Differential Scanning Calorimetry (DSC) studies	38
Powder- X Ray Diffractometry (P-XRD)	38
4.5.2 Particle size and Polydispersity index (PDI)	38
4.5.3 Zeta Potential	39
4.5.4 TEM (Transmission Electron Microscopy)	39
4.5.5 AFM (Atomic Force Microscopy)	39
4.5.6 Encapsulation Efficiency (EE)	39
4.5.7 Cumulative Percentage Drug Release (%CDR)	40
4.5.8 Stability studies and calculation of shelf life	41

	4.5.9 Hemocompatibility studies	41-
		42
	4.5.10 In vitro cytotoxicity	43
	4.5.11 Pharmacokinetic studies	44
	4.5.12 In vivo biochemical estimations	45
	4.5.13 In vivo anticancer activity	46
	4.5.14 Statistical analysis	47
<b>5</b>	<b>Results &amp; Discussion</b>	
	5.1 Preformulation study	
	5.1.1 HPLC & bioanalytical method development & validation	49
	5.1.2 Synergism analysis of ratiometric drug combination	57
	5.2 Result & Discussion of Nanostructured lipid carriers	
	5.2.1 Optimization of process and product Parameters for Blank NLCs	58
	5.2.2 The Plackett Burman design (PBD)	61
	5.2.3 The Box-Behnken design (BBD): The response surface methodology	64
	5.2.4 Optimization of NLCs:	72
	5.2.5 Characterization studies	
	Fourier Transformed Infrared studies (FTIR)	73
	Differential Scanning Calorimetry (DSC) studies	75
	Powder- X Ray Diffractometry (P-XRD)	76
	5.2.6 Particle size (PS), Polydispersity index (PDI), Zeta potential (ZP), Entrapment efficiency (EE)	77
	5.2.7 Surface morphology studies	78
	5.2.8 Cumulative Percentage Drug Release (%CDR)	79
	5.2.9 Stability studies and calculation of shelf life	82
	5.2.10 Evaluation of haemolysis	84
	5.2.11 Platelet aggregation test	85
	5.2.12 Cytotoxicity studies	88
	5.2.13 Pharmacokinetic studies	91
	5.2.14 In vivo biochemical estimations	94

5.2.15	In vivo anticancer activity	97
5.3	Result & Discussion of polymeric nanoparticles	
5.3.1	Experimental design	99
5.3.2	Optimization of Polymeric nanoparticles	110
5.3.3	Characterization studies	110
	Fourier Transformed Infrared studies (FTIR)	
	Differential scanning calorimetry (DSC)	113
	Powder- X Ray Diffraction study (P-XRD)	114
5.3.4	Particle size (PS), Polydispersity index (PDI), Zeta potential (ZP), Entrapment efficiency (EE)	115
5.3.5	Surface morphology studies	116
5.3.6	Cumulative Percentage Drug Release (%CDR)	117
5.3.7	Stability studies	120
5.3.8	Evaluation of haemolysis	122
5.3.9	Platelet aggregation test	123
5.3.10	In vitro cytotoxicity study	125
5.3.11	Pharmacokinetic studies	128
5.3.12	In vivo biochemical estimations	132
5.3.13	In vivo anticancer activity	134
<b>6</b>	<b>Conclusion</b>	137
<b>7</b>	<b>References</b>	139
<b>8</b>	<b>Publications</b>	150

---